Literature DB >> 8990099

Production and roles of IL-6, IL-10, and IL-13 in B-lymphocyte malignancies and in B-lymphocyte hyperactivity of HIV infection and autoimmunity.

D Emilie1, W Zou, R Fior, L Llorente, A Durandy, M C Crevon, M C Maillot, I Durand-Gasselin, M Raphael, M Peuchmaur, P Galamaud.   

Abstract

We analyzed the production and the roles of IL-6, IL-10, and IL-13 in B-lymphoid malignancies and in specific diseases with B-lymphocyte hyperactivity. Both IL-13 and IL-10 genes are expressed in B-cell lymphomas. However, their contribution to tumor progression is unclear. In certain lymphoproliferative disorders that develop in transplanted patients, IL-6 is produced by malignant cells and is a major factor of their proliferation. In other lymphomas, the IL-6 gene is expressed only in malignancies where differentiated malignant cells are present. In these lymphomas, IL-6 is produced by stromal cells, and the malignant cells express the IL-6 receptor. In patients with HIV infection, the level of production of IL-6, IL-10, and IL-13 is not higher than those of other conditions with immune activation. However, IL-6 contributes to increased production of IgG and IgA in vivo. In Castleman's disease, IL-6 is produced in the lymph node germinal centers, partly originating from follicular dendritic cells, which may explain some of the pathogenesis of this disease. In systemic lupus erythematosus, the critical cytokine is IL-10, which is produced in large amounts by B lymphocytes and monocytes and is responsible for autoantibody production. Taken together, these data emphasize the roles of IL-6 and IL-10, usually produced by nonlymphoid cells, on B lymphocytes, either malignant or hyperactivated.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 8990099     DOI: 10.1006/meth.1996.0397

Source DB:  PubMed          Journal:  Methods        ISSN: 1046-2023            Impact factor:   3.608


  4 in total

1.  Cellular tropism and viral interleukin-6 expression distinguish human herpesvirus 8 involvement in Kaposi's sarcoma, primary effusion lymphoma, and multicentric Castleman's disease.

Authors:  K A Staskus; R Sun; G Miller; P Racz; A Jaslowski; C Metroka; H Brett-Smith; A T Haase
Journal:  J Virol       Date:  1999-05       Impact factor: 5.103

Review 2.  Malignancy and systemic lupus erythematosus.

Authors:  Sasha Bernatsky; Ann Clarke; Rosalind Ramsey-Goldman
Journal:  Curr Rheumatol Rep       Date:  2002-08       Impact factor: 4.592

3.  Epstein-Barr virus-related diffuse large B-cell lymphoma type methotrexate-associated lymphoproliferative disorders presenting in the adrenal gland.

Authors:  Kazuki Doi; Mototsugu Muramaki; Tetsuro Yamamoto; Daiki Katsura; Hiroyuki Fukunaga; Kosuke Takahashi; Minori Matsumoto; Yuji Yamada
Journal:  IJU Case Rep       Date:  2022-03-08

Review 4.  Immune response in LPD during methotrexate administration (MTX-LPD) in rheumatoid arthritis patients.

Authors:  Shuntaro Saito; Tsutomu Takeuchi
Journal:  J Clin Exp Hematop       Date:  2019
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.